AstraZeneca and Owkin announced a three-year licensing agreement for Owkin's K Pro, an autonomous 'AI Scientist' platform.
Owkin will develop custom biopharma AI agents to automate research and competitive intelligence, analyzing clinical trials, recruitment trends, outcomes, and patents.
K Pro integrates multimodal data from over 800 hospitals and will be embedded into AstraZeneca’s IT infrastructure and workflows.
The deal builds on prior collaboration for an AI tool to pre-screen germline BRCA mutations in breast cancer patients.
Announcement made on May 13, 2026; financial terms undisclosed.